Bristol-Myers Squibb Co has the GF Score of 57, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Bristol-Myers Squibb Co
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Bristol-Myers Squibb Co (LIM:BMY) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Bristol-Myers Squibb Co GF Score Related Terms
LIM:BMY vs PFE, GILD, AMGN: GF Score Comparison
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co GF Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's GF Score distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's GF Score falls into.
Bristol-Myers Squibb Co (LIM:BMY) has a GF Score of 57 as of Jul. 07, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Bristol-Myers Squibb Co and its competitors. This is 15% below median its historical median of 67.00. Over the past decade, Bristol-Myers Squibb Co's GF Score has ranged from 55.00 to 82.00.
Is Bristol-Myers Squibb Co's GF Score too high?
Bristol-Myers Squibb Co's current GF Score of 57 is 15% below median its 10-year median of 67.00. Over the past 10 years, this metric has ranged from a low of 55.00 to a high of 82.00. Overall, Bristol-Myers Squibb Co has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's GF Score compare to PFE and GILD?
Bristol-Myers Squibb Co's GF Score of 57 can be compared against companies in the Drug Manufacturers industry. Historically, Bristol-Myers Squibb Co's own GF Score has ranged from 55.00 to 82.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current GF Score is 57, which is 15% below median its own 10-year median of 67.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (LIM:BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is $48.23, compared to a current price of $56.98 — trading 18.1% above its estimated fair value. The current GF Score is 57, which is 15% below median its 10-year median of 67.00. Bristol-Myers Squibb Co's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Bristol-Myers Squibb Co (LIM:BMY), the current GF Score is 57 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bristol-Myers Squibb Co (LIM:BMY) Overvalued in 2026?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued.
The current stock price of $56.98 is trading 18.1% above its estimated GF Value™ of $48.23.
GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.
Key valuation signals for LIM:BMY:
GF Score: 57 (15% below median its 10-year median of 67.00)
GF Value™: $48.23 vs. price of $56.98 (18.1% above fair value)
No single metric tells the full story. See the LIM:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
57GF Score
Get the complete analysis for LIM:BMY
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIM:BMY has been successfully added to your 